OncLive TV

John M. Burke, MD, discusses the role of tazemetostat in EZH2-mutated follicular lymphoma.

Pankti Reid, MD, MPH, discusses remaining challenges regarding the management of immune-related adverse effects.

Edward B. Garon, MD, discusses unique challenges of the coronavirus disease 2019 in lung cancer.

Edward B. Garon, MD, discusses the expanding treatment landscape in lung cancer.

Edward Chu, MD, MMS, discusses the impact of the phase 3 MK-3475-177/KEYNOTE-177 trial in ​metastatic colorectal cancer.

Howard A. “Skip” Burris, III, MD, FASCO, FACP, discusses ​the utility of sacituzumab govitecan-hzi​y in metastatic triple-negative breast cancer.

John A. Abraham, MD, FACS, discusses future research efforts in tenosynovial giant cell tumor.

Ajai Chari, MD, discusses next steps with belantamab mafodotin-blmf and combination studies in multiple myeloma.

David A. Reardon, MD, discusses the design of a phase 1/2 trial with INO-5401 and INO-9012 in glioblastoma.

Shambavi Richard, MD, discusses treatment according to transplant eligibility in multiple myeloma. 

Neeta Somaiah, MD, discusses ​remaining challenges in soft tissue sarcoma.

Douglas B. Johnson, MD, MSCI, discusses the limitations of biomarkers in melanoma.

Kevin Harrington, BSc, MBBS, PhD, MRCP, FRCP, FRCR, discusses the randomized phase 3 KEYNOTE-048 trial in recurrent/metastatic head and neck squamous cell carcinoma.

Praful K. Ravi, MD, discusses the evolving treatment landscape of advanced bladder cancer.

Eric Jonasch, MD, discusses the role of inhibiting hypoxia-inducible factor-2α in Von Hippel-Lindau disease–associated renal cell carcinoma.

Mikkael A. Sekeres, MD, discusses staging patients with myelodysplastic syndromes.

Anna C. Pavlick, DO, discusses the longer follow-up of the phase 2 EMPOWER-CSCC-1 study with cemiplimab in cutaneous squamous cell carcinoma.

Jennifer L. Atlas, MD, discusses the promise of cemiplimab in the treatment of patients with locally advanced cutaneous squamous cell carcinoma.

Christine Sam, MD, discusses strategies to mitigate the risk of the coronavirus disease 2019 in elderly patients with cancer.

Nabil F. Saba, MD, FACP, discusses ​emerging sequencing ​strategies in head and neck cancer. 

Sandra Cuellar, PharmD, BCOP, discusses challenges with ​data extrapolation for biosimilars. 

Denise Yardley, MD, discusses challenges with ​resistance mechanisms in hormone receptor–positive, HER2-negative breast cancer. 

Gina Z. D'Amato, MD, discusses the utility of next-generation sequencing in patients with stage I, II, or III sarcoma.

Erika P. Hamilton, MD, discusses updated data from the phase 2 HER2CLIMB trial examining tucatinib in patients with HER2-positive breast cancer and brain metastases.

Nilanjan Ghosh, MD, PhD, compares different BTK inhibitors in B-cell malignancies.

Joyce A. O'Shaughnessy, MD, discusses the utility of tucatinib in HER2-positive breast cancer with brain metastases.

David A. Reardon, MD, discusses the role of INO-5401 and INO-9012 in glioblastoma.

Mansoor Raza Mirza, MD,  discusses the safety ​profile of niraparib in combination with bevacizumab in platinum-sensitive recurrent ovarian cancer.

Paul A. Bunn, Jr MD, discusses potentially targeting HER3 in non–small cell lung cancer.

Erika P. Hamilton, MD, discusses the efficacy of fam-trastuzumab deruxtecan-nxki in HER2-low breast cancer.